BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Allied Healthcare Products

Alpha Pro Tech

Cerus

Co-Diagnostics

Dyadic International Inc., DE

Inovio Pharmaceuticals

Lakeland Industries

Moderna

NanoViricides

Novavax

Vir Biotechnology

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

12 Stocks Surging That Could Help Treat or Fight Coronavirus

Gilead Sciences

But it's important to separate the current panic from the real potential for these biotechs.

5 Biotech Stocks to Watch With the Coronavirus Scare

Aethlon Medical

AstraZeneca

Cleveland BioLabs

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

Worries about the spread of a virus in China are driving the biotech's shares higher.

Why BioCryst Pharmaceuticals  Stock Is Jumping Today

Shares of several vaccine makers were on the rise Tuesday following reports of a spreading coronavirus outbreak in Asia.

4 Vaccine Stocks Making Big Moves Amid Coronavirus Outbreak

RESEARCH TRIANGLE PARK, N.C., Jan.  15, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointments of Charles Gayer as chief commercial officer and Allen Hodge as vice president and general manager for the United States.

BioCryst Strengthens Commercial Rare Disease Leadership

RESEARCH TRIANGLE PARK, N.C., Jan.  06, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 20,000 shares of BioCryst common stock on December 31, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under  NASDAQ Listing Rule 5635(C)(4)

BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

BioCryst Submits NDA for Hereditary Angioedema Candidate

RESEARCH TRIANGLE PARK, N.C., Dec.  11, 2019  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.

BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

RESEARCH TRIANGLE PARK, N.C., Dec.  04, 2019  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 142,500 shares of BioCryst common stock on November 29, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c) (4).

BioCryst: The Stock Price Is At A Turning Point

RESEARCH TRIANGLE PARK, N.C., Nov.  18, 2019  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 43,620,690 shares of its common stock, including 5,689,655 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.  The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters’ option to purchase additional shares, were approximately $63.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst. 

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) completed a $55 million equity raise earlier this week.

Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

RESEARCH TRIANGLE PARK, N.C., Nov.  13, 2019  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 37,931,035 shares of its common stock, offered at a price to the public of $1.45 per share.  The gross proceeds from this offering to BioCryst are expected to be $55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst. 

BioCryst Prices Public Offering of Common Stock

BioCryst: A New Actor In The Alternative Pathway Inhibition Field

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2019 Results - Earnings Call Transcript

BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -60.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates

—Results of the APeX-S and APeX-2 trials show patients taking 150 mg of oral, once daily BCX7353 achieved a stable average attack rate of ≤ 1 attack per month at 48 weeks—

New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAE

—Agreement includes up to $42 million of upfront and potential milestone payments plus royalties on net sales—

BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks       

—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID—

BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients

Results of phase I competitor ACH5228 for Factor D have set the bar very high for BCX9930.

BioCryst: Much At Stake In Next Phase I Results Of BCX9930

$14 million in non-dilutive capital added by year end $14 million in non-dilutive capital added by year end

U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

RESEARCH TRIANGLE PARK, N.C., Sept.  24, 2019  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on Friday, October 4, 2019 at 12:35 p.m. ET.

BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

Investors are thrilled with a new addition to BioCryst's board of directors.

Here's Why BioCryst Pharmaceuticals Popped Today

RESEARCH TRIANGLE PARK, N.C., Sept.  23, 2019  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to its board of directors.

News for BioCryst Pharmaceuticals Stock (BCRX)